Back to News
Market Impact: 0.4
Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Corbus Pharmaceuticals reported positive topline Phase 1b CANYON-1 results for oral obesity candidate CRB-913. The 60 mg daily dose achieved statistically significant and clinically meaningful mean weight loss of 5% at 12 weeks, supporting further development of the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
CRBP0.82
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- RBC Capital cuts Sprouts Farmers Market stock rating on margin concerns
- Microsoft's Big Bets on AI Start to Pay Off